person
as of 2026-07-01Deepak Cyril D'Souza, MD
Deepak C D'Souza, MDDeepak C. D'Souza, MDDeepak D'Souza, MD
at a glance
Roles: Principal Investigator, Author
KOL signal score 7
1 publications · 0 high-value
Cross-drug reach: 1 competitor drugs
Synthesized from structured facts only — each point cited above.
Profile
Affiliation
Yale Univerisity, School of Medicine
Roles
Principal Investigator, Author
KOL signal
7
Publications
1 (0 high-value)
Trial investigator
yes
Publishes on
1 drugs
Trials led
8
Genetics of Cannabis Use Disorder and Cannabinoid Response in Humans
NCT06058702Phase 1Recruiting
Imaging Cannabinoid Receptors Using Positron Emission Tomography (PET) Scanning
NCT01730781—Recruiting
A Double-Blind Trial of Adjunctive Valacyclovir to Improve Cognition in Early Phase Schizophrenia
NCT02008773Phase 2Completed
D-Serine for Enhancing Cognitive Retraining for the Treatment of Schizophrenia
NCT00237848Phase 3Completed
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone: Sub-Study I
NCT02811939Phase 1Completed
Translational Neuroscience Optimization of GlyT1 Inhibitor
NCT01911676Phase 2Completed
Cannabinoids, Neural Synchrony, and Information Processing
NCT00708994Early Phase 1Completed
Testing the Interactive Effects of Delta-9-Tetrahydrocannabinol and Pregnenolone
NCT02576912Phase 1Completed
Publications & congress
1
Lower Muscarinic M1 Receptor Availability in Schizophrenia: In Vivo PET Evidence.
Biological psychiatry · 2026
Facts & assertions
0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
publishes on
PRINCIPAL_INVESTIGATOR
trial